Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Few topics in the MCAS world have generated as much excitement — and as much premature confidence — as the idea of using GLP-1 receptor agonists at sub-therapeutic doses to calm mast cell activation. Social media is filled with enthusiastic testimonials. Clinician blogs have declared a "game-changer." And compounding pharmacies are already marketing microdosed tirzepatide directly to the MCAS community.

As someone who treats clients with MCAS daily, I find the biological rationale genuinely interesting. But I also think the MCAS community deserves a more careful accounting of what we actually know, what we don't, and what it means to treat a hypothesis as though it were established medicine.

This post is my attempt at that accounting.

What We Actually Have: One Retrospective Case Series

The foundation for this entire conversation is a single publication: a retrospective case series by Afrin, Weinstock, Dempsey, and colleagues, published in The American Journal of the Medical Sciences in July 2025 (Afrin LB, Weinstock LB, Dempsey TT, et al. "Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome." Am J Med Sci. 2025).

The key findings: 47 clients with refractory MCAS (mean age 39, 89% female) were treated with at least one GLP-1 receptor agonist — semaglutide, liraglutide, or tirzepatide depending on the case. Eighty-nine percent demonstrated clinical benefit across inflammatory, neurologic, gastrointestinal, and autonomic symptoms. Improvements were often rapid, emerging within hours to days. Mean weight loss was 13% (median 10.6%), and no client became underweight.

These are compelling numbers. They are also numbers that require context.

What a Retrospective Case Series Can and Cannot Tell Us

A retrospective case series is the starting point for clinical investigation, not the finish line. This study had no placebo group, no blinding, no randomization, and no statistical comparison against another treatment. The clients were selected by their own treating physicians — the same physicians who authored the paper — creating inherent selection bias. We do not know how many clients tried GLP-1 receptor agonists and did not improve, because those clients may not have been included.

The authors themselves are transparent about these limitations. They describe their findings as "a clarion call for rigorous, systematic investigation" — language that explicitly acknowledges they are proposing a hypothesis, not confirming one.

This matters because the distance between "89% responded in a case series" and "this treatment works for MCAS" is enormous. History is littered with therapies that looked transformative in case series and failed in controlled trials. The MCAS community, which has been burned by overpromised interventions before, deserves clinicians who are honest about this gap.

The Biological Rationale: Plausible but Incomplete

The mechanistic argument for GLP-1 receptor agonists in MCAS rests on several observations, each of which is real but none of which constitutes proof of therapeutic efficacy in MCAS.

GLP-1 receptors are reported on immune cells, possibly including mast cells — but this evidence is weaker than it is often presented. The Afrin case series states that GLP-1 receptors are present on many cell types beyond their classical pancreatic and CNS targets, including mast cells. It is worth being precise about what supports this. The paper's claim regarding mast cells rests on preclinical work — a wound-healing study and a rodent myenteric-neuron co-culture study — rather than direct demonstration of functional GLP-1 receptors on human mast cells.

More broadly, the entire field of "GLP-1 receptors on immune cells" is currently contested. A 2025 study from Daniel Drucker's laboratory (Wong CK et al. "Reassessment of antibody-based detection of the murine T cell GLP-1 receptor." Cell Metab. 2025) demonstrated that several widely used GLP-1 receptor antibodies lack specificity, generating false-positive signals even in tissue from GLP-1 receptor knockout animals. Because much of the immune-cell GLP-1 receptor literature relies on exactly these antibody methods, confident claims about receptor expression on any given immune cell — mast cells included — should be treated with caution. If a receptor is genuinely present on the cell, it is biologically reasonable to hypothesize that activating it could modulate cell behavior. But receptor expression is not the same as therapeutic effect, and in this specific case the receptor expression itself is not firmly established.

GLP-1 receptor agonists have demonstrated anti-inflammatory effects independent of weight loss. A comprehensive 2025 review by Wong and Drucker in the Journal of Clinical Investigation (Wong CK, Drucker DJ. "Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits." J Clin Invest. 2025;135(21):e194751) documents that GLP-1 receptor agonist signaling reduces systemic and tissue inflammation through both weight loss–dependent and weight loss–independent mechanisms. In the SUSTAIN and PIONEER trials, for example, only 20–60% of the observed C-reactive protein reduction could be attributed to changes in weight and glycemia.

These anti-inflammatory effects appear to involve inhibition of NF-κB signaling and reduction of proinflammatory cytokine production — pathways that are directly relevant to mast cell mediator release. A 2024 study from Drucker's lab (Wong CK et al. "Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation." Cell Metab. 2024) demonstrated that central GLP-1 receptor activation inhibits TLR-induced inflammation, adding another potential mechanistic layer.

The problem is that none of this research was conducted in the context of MCAS. The anti-inflammatory evidence comes from diabetes, obesity, cardiovascular, and renal disease populations. Whether these mechanisms translate meaningfully to the dysregulated mast cell biology of MCAS — where the fundamental problem is aberrant mediator release driven by heterogeneous somatic mutations in mast cell regulatory genes — is an untested assumption.

The Microdosing Question: Even Less Evidence

If the evidence for GLP-1 receptor agonists in MCAS is preliminary, the evidence for microdosing is essentially nonexistent in the formal literature.

The Afrin case series does not specify a single standardized dosing protocol, and individual doses varied among the 47 patients. Secondary clinical commentaries interpreting the paper — including Dr. Jill Carnahan's review and a widely-shared patient account — describe an approach of initiating at roughly 10–25% of standard diabetes or obesity doses. For tirzepatide, where the FDA-approved starting dose is 2.5 mg once weekly, this would translate to approximately 0.25–0.625 mg weekly. Readers should note this 10–25% figure is drawn from secondary interpretations of the paper rather than a formally validated dosing guideline, and clinicians considering this should review the primary text directly.

There are no randomized controlled trials of tirzepatide at any dose for MCAS. There are no prospective studies. There are no pharmacokinetic studies examining receptor occupancy, anti-inflammatory thresholds, or mast cell stabilization at sub-therapeutic doses. The entire microdosing framework is extrapolated from two premises:

1. MCAS clients tend to be medication-sensitive and may respond to lower doses.
2. Anti-inflammatory effects of GLP-1 receptor agonists may have a lower threshold than metabolic effects.

Both of these premises are plausible. Neither has been formally tested for this specific application.

The most detailed patient-level account of tirzepatide microdosing for MCAS comes from a well-documented personal report by Jodi Ettenberg, who has written extensively about her experience using 250 µg (0.25 mg) — one-tenth of the standard starting dose — every five days rather than weekly. She reports reduced joint and nerve pain, fewer MCAS flares, expanded food tolerance, and no weight loss at this dose. This is a carefully documented n=1, and I respect the intellectual honesty of her account. But an n=1 is not evidence of efficacy. It is a signal that merits investigation.

Practical Considerations If You Are Considering This Approach

I am not writing this post to discourage exploration. I am writing it to insist on intellectual honesty about the evidence level. If, after understanding these limitations, a clinician and client decide to trial tirzepatide for refractory MCAS, the following practical considerations emerge from the available literature and clinical commentary.

Dosing range. The working range discussed in the literature is approximately 0.25–0.625 mg weekly, corresponding to 10–25% of the 2.5 mg standard starting dose. Some clinicians and clients have used dosing intervals shorter than seven days (every five days) to address symptom recurrence at the end of the dosing window — a pattern consistent with tirzepatide's approximately five-day half-life. These are not evidence-based protocols. They are clinical extrapolations.

Formulation. Branded tirzepatide (Mounjaro, Zepbound) is available only in pre-filled pens with a minimum dose of 2.5 mg. Microdosing requires compounded tirzepatide, typically supplied in multi-dose vials at concentrations of 2.5–5 mg/mL and drawn up with insulin syringes. The quality and purity of compounded preparations is pharmacy-dependent, and the FDA's regulatory posture toward compounded GLP-1 receptor agonists continues to evolve. Clinicians should use only 503B-registered outsourcing facilities or state-licensed compounding pharmacies with documented certificates of analysis.

Monitoring. There are no validated monitoring protocols for this off-label use. At minimum, I would suggest tracking a symptom diary with standardized MCAS symptom scoring, body weight, and basic metabolic labs at baseline and regular intervals. Gastrointestinal symptoms — nausea, delayed gastric emptying, constipation — are the most common adverse effects of GLP-1 receptor agonists at standard doses and should be monitored even at microdoses, particularly in clients with comorbid Ehlers-Danlos syndrome or known gastroparesis.

Expectations. Relapse upon discontinuation was common in the Afrin case series. This is consistent with the broader GLP-1 receptor agonist literature across all indications — weight regain, liver lab reversion, symptom return. If this medication helps, it likely needs to be continued indefinitely, which has implications for cost, access, and the regulatory landscape around compounded preparations.

Where This Hypothesis Needs to Go

The Afrin case series is a legitimate contribution to the literature. The biological rationale is grounded in real receptor biology and real anti-inflammatory data. The clinical observations — rapid, multi-system improvement in refractory MCAS clients — are the kind of signal that should prompt formal investigation.

What this hypothesis needs, and what the MCAS community deserves, includes:

• Prospective, controlled trials specifically designed for MCAS, with standardized diagnostic criteria, predefined endpoints, and placebo controls.
• Dose-finding studies that examine whether sub-therapeutic doses actually achieve meaningful mast cell stabilization, and if so, at what threshold.
• Pharmacokinetic and pharmacodynamic data at microdose ranges — receptor occupancy, mediator level changes, inflammatory biomarker responses.
• Long-term safety data in a population that is characteristically medication-sensitive and often managing multiple comorbidities.
• Head-to-head comparisons with established MCAS therapies — how does this compare to optimized antihistamine regimens, cromolyn, or other mast cell stabilizers?

Until we have at least some of this data, the honest framing is: this is a biologically plausible hypothesis supported by preliminary clinical observations. It is not an established treatment. Clinicians who present it as such are getting ahead of the evidence.

My Position

I am watching this space closely. The mechanistic data is accumulating, and the Afrin case series is not a fluke — the clinical observations are too consistent across multiple independent authors and too rapid in onset to be easily dismissed as placebo effect alone. When refractory clients ask me about this option, I discuss it honestly: what the evidence actually shows, what it doesn't, what the risks are, and what "off-label and pre-RCT" means in practical terms.

I believe the MCAS community is best served by clinicians who can hold two ideas simultaneously: this might work, and we don't know yet whether it does. That tension is not comfortable, but it is honest.

As the Afrin paper's authors wrote, their findings should serve as a call for rigorous investigation. I agree. In the meantime, I will continue to follow the evidence where it leads — not where I hope it will go.

References

1. Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. Am J Med Sci. Published online July 15, 2025. doi:10.1016/j.amjms.2025.07.006

2. Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits. J Clin Invest. 2025;135(21):e194751. doi:10.1172/JCI194751

3. Wong CK, McLean BA, Baggio LL, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024;36(1):130-143. doi:10.1016/j.cmet.2023.11.009

4. Wong CK, Yusta B, Tong JCL, Broichhagen J, Hodson DJ, Drucker DJ. Reassessment of antibody-based detection of the murine T cell GLP-1 receptor. Cell Metab. 2025. doi:10.1016/j.cmet.2025.06.012

5. Rojas M, et al. Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. Can J Physiol Pharmacol. 2025. doi:10.1139/cjpp-2025-0148

6. Patel S, Niazi SK. Emerging frontiers in GLP-1 therapeutics: a comprehensive evidence base (2025). Pharmaceutics. 2025;17(8):1036. doi:10.3390/pharmaceutics17081036

7. Drucker DJ. The expanding benefits of GLP-1 medicines. Cell Rep Med. 2025;6(7):102214. doi:10.1016/j.xcrm.2025.102214

About Dr. Kim

Yoon Hang Kim, MD, MPH, is board-certified in Preventive Medicine with more than 20 years of experience in integrative and functional medicine. A University of Arizona/Andrew Weil Center for Integrative Medicine fellowship-trained physician, he holds additional certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. Dr. Kim specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and more than 20 published articles.

www.yoonhangkim.com | www.directintegrativecare.com